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Abnormally enhanced N-methyl-D-aspartate (NMDA) receptor function is implicated in Huntington’s disease
(HD). In this issue of Neuron and a recent issue ofNatureMedicine, an abnormal balance between the activity
of NMDA receptors at synaptic (prosurvival) and extrasynaptic (proapoptotic) sites has been uncovered in
a cellular and a mouse model of HD.Huntington’s disease (HD) is a progressive
neurological disorder inherited in an auto-
somal, dominant fashion. The symptoms
include abnormal dance-like movements,
cognitive disturbances, and disorders of
mood, many of which precede onset of
the motor abnormalities. The HD gene is
located on the short arm of chromosome
4 and contains an expansion in the nor-
mal number of CAG (glutamine) repeats
(generally >40) (The Huntington’s Disease
Collaborative Research Group, 1993).
Neuropathologically, HD is characterized
primarily by neuronal loss in striatum
and cortex, and specifically targets the
medium-sized spiny striatal neurons
(MSNs). The protein coded, huntingtin
(htt), is highly conserved and ubiquitous.
A number of roles for htt have been uncov-
ered, but the precise mechanism(s) by
which mutant (m)htt causes dysfunction
and ultimate degeneration of neurons
remains an area of intense study. Htt is
a cytoplasmic protein closely associated
with vesicle membranes, microtubules,
and synaptic proteins, suggesting that it
may have a role in vesicle trafficking,
exocytosis, endocytosis, and synaptic
function. It is probable that mhtt causes
abnormal synaptic transmission involving
a combination of pre- and postsynaptic
mechanisms. Other possibilities exist for
abnormal mtt function and among the
more prominent are transcriptional dysre-
gulation and altered autophagy.
Early models of HD, before identifica-
tion of the gene, were based on treatments
that produced degeneration of MSNs that
replicated the human neuropathology.The most prominent was excitotoxicity
in which quinolinic acid, a selective
N-methyl-D-aspartate (NMDA) receptor
agonist, was used to produce striatal
degeneration (Coyle, 1979). Thus, abnor-
malities in glutamate transmission and
especially postsynaptic NMDA receptors
became important in the study of HD.
Although these toxic models provided
useful information, they did not allow
mechanistic examination of the temporal
course of the disease or of cause-effect
relationships. The subsequent introduction
of genetic mouse models of HD demon-
strated that severe neuronal dysfunction
precedes degeneration and is probably
the major determinant of a number of
symptoms.
Studies designed to test the excitotox-
icity hypothesis in genetic mouse models
of HD have generally provided evidence
that NMDA receptor function is enhanced
in MSNs (Fan and Raymond, 2007).
However, human trials blocking NMDA
receptor function have been disap-
pointing, demonstrating little or no thera-
peutic value. The reasons for such differ-
ences are unclear but may relate to the
fact that manyhuman treatments occurred
during later stages of the disorder when
significant degeneration was already
present or that NMDA receptors are differ-
entially affected in different regions of the
brain in HD or that blockade of all NMDA
receptors is not the correct approach.
Recently, a dual role for NMDA recep-
tors has been uncovered depending upon
the location of the receptor to synaptic or
extrasynaptic sites (Papadia and Hardi-Neuron 65ngham, 2007). Synaptic NMDA receptors
activate cellular survival pathways while
extrasynaptic receptors activate path-
ways that lead to cell death (Figure 1).
Thus, the balance of activity or the
numbers of each of the types of NMDA
receptors at each location can sway the
outcome between cell survival and cell
death. Using this idea, recent research has
studied differential function of synaptic and
extrasynaptic NMDA receptors in HD.
In this issue, Milnerwood et al. (2010)
provide the first electrophysiological evi-
dence that the balance between syn-
aptic and extrasynaptic NMDA recep-
tors is disrupted in MSNs in a mouse
model of HD. Their experiments demon-
strate increased extrasynaptic NMDA
receptor-induced currents and signaling
in the YAC128 mouse model of HD. This
increased activity requires caspase-6
cleavage, a step necessary for formation
of the toxic mhtt fragment, and involves
NMDA receptors that contain the NR2B
subunit. Furthermore, they provide tanta-
lizing new evidence that treatment with
memantine, an NMDA antagonist that at
low dosages antagonizes extrasynaptic
but not synaptic NMDA receptors,
reverses the decrease in the nuclear
cyclic AMP receptor element-binding pro-
tein (CREB) activity induced by activation
of extrasynaptic NMDA receptors and
improves performance of YAC128 mice
on a rotarod motor learning task. These
outcomes signify that the increased extra-
synaptic NMDA activity is deleterious in
this mouse model and, when blocked, its
negative effects can be prevented., January 28, 2010 ª2010 Elsevier Inc. 145
Figure 1. Synaptic and Extrasynaptic Receptors in HD
The left side shows synaptic and extrasynaptic NMDA receptors functioning in a balanced manner in the
normal condition. On the right in HD there is an increase in extrasynaptic NMDA receptor function due to
increase in either the number of receptors and/or an increase in extracellular glutamate that shifts the func-
tional balance toward the extrasynaptic receptors enhancing the proapoptotic pathway.
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(Okamoto et al., 2009) provides strikingly
similar outcomes demonstrating a rela-
tionship between synaptic and extrasy-
naptic NMDA receptor activity and inclu-
sion formation in cultured rat cortical
cells expressing mhtt and in the YAC128
mouse model of HD. Activation of synaptic
NMDA receptors made cultured mhtt-
expressing cortical cells more resistant
to cell death by inducing mhtt inclu-
sions via a mechanism involving the T
complex-1 (TCP-1) ring complex (TRiC).
In contrast, activation of extrasynaptic
NMDA receptors reduced inclusions and
increased the vulnerability of mhtt-ex-
pressing cortical neurons by impairing the
neuroprotective CREB-peroxisome prolif-
erator-activated receptor-g coactivator-
1a (PGC-1a) cascade and increasing the
level of the small binding protein Rhes,
which has been shown to sumoylate and
disaggregate mhtt (Subramaniam et al.,
2009). Of clinical importance, Okamoto
et al. (2009) also showed that treatment
of YAC128 mice with low but not high
dosages of memantine ameliorated
adverse neuropathological and behav-
ioral effects.
There are a number of important points
and questions relevant to HD and poten-
tially other neurodegenerative disorders
emanating from these reports. First and
primary is that, in HD, therapeutic treat-
ments aimed at blocking NMDA receptors
should be designed to target extrasynap-
tic receptors. Memantine, at low dosages,
more selectively targets these receptors,146 Neuron 65, January 28, 2010 ª2010 Elseand a recent, but small, open label human
clinical trial showed promising results
(Ondo et al., 2007). In addition, in that trial
virtually all patients were also being
treated with tetrabenazine, a drug that
affects catecholamine systems in the
brain and was recently approved for use
in HD by the FDA. Clearly, there is now
strong support for larger and more
controlled trials with memantine in HD.
Second, although there is clear evidence
for altered selectivity of activation of
synaptic and extrasynaptic NMDA recep-
tors, where does this activation and the
‘‘extra’’ glutamate come from, and why
is there more of it in HD? Normally, excit-
atory glutamatergic synapses in the stria-
tum are derived from neurons in the cortex
and thalamus. Since extrasynaptic NMDA
receptors require glutamate spillover
and higher activity for their activation
compared to synaptic receptors, espe-
cially in HD as demonstrated by Milner-
wood et al. (2010), what is the source of
this greater activity in HD? Electrophysio-
logical studies in genetic HD mouse
models demonstrated early and progres-
sive biphasic changes in synaptic trans-
mission in the corticostriatal pathway,
as shown by increases followed by
decreases in excitatory synaptic events
(Cepeda et al., 2007; Joshi et al., 2009).
There also appears to be a progressive
disconnection between cortex and stria-
tum that might predict a redistribution of
glutamate receptors to extrasynaptic
sites (Cepeda et al., 2007). There is signif-
icant evidence for pathological changesvier Inc.in the cortex as well, and many of these
appear to precede gross pathology in
the striatum in humans (Rosas et al.,
2005). We do not yet know if the balance
of synaptic and extrasynaptic NMDA
receptor function is altered in the cortex
in HD. However, unlike the striatum,
NMDA receptor activity does not appear
to be enhanced in the cortex (Andre´
et al., 2006). Synaptic changes in the
cortex in HD also are complex, involving
both excitation and inhibition (Cummings
et al., 2009). But unlike the striatum, there
is a progressive increase in excitatory
synaptic inputs to pyramidal neurons
that appears to be associated with a
progressive decrease in inhibition. Thus,
in contrast to the striatum, increased exci-
tation in the cortex may not be a conse-
quence of alterations in NMDA receptor
activity. Other possibilities for the sources
of the increased extrasynaptic glutamate
or NMDA receptors in the striatum are
leakage of glutamate via reverse trans-
port or some other mechanism adversely
affected by mhtt (Re et al., 2006) or
possibly abnormal insertion and migration
of receptors between synaptic and extra-
synaptic sites in HD (Tovar and West-
brook, 2002).
Another issue raised is the relationship
between extrasynaptic NMDA receptor
activation and abnormal protein folding,
which generates the cellular inclusions in
HD. Okamoto et al. (2009) provide strong
evidence that activation of the cell survival
pathway increases mhtt aggregation,
indicating that the formation of aggre-
gates may be a positive response of the
cell. In contrast, activation of extrasynap-
tic NMDA receptors does the opposite.
Misfolded proteins are associated with a
number of neurodegenerative diseases,
like Alzheimer’s and Parkinson’s diseases
as well as HD. It becomes important to
know if there is a common neurophysio-
logicalmechanism modifying and possibly
controlling protein misfolding in these
disorders.
These exciting findings have provided
new targets for the therapeutic treatment
of HD. Together the two studies link
abnormal neuronal electrophysiology
with the deleterious activity of extrasy-
naptic NMDA receptors. They provide
insight into the signaling pathways
involved and demonstrate that treatment
with a compound that selectively blocks
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Previewsextrasynaptic NMDA receptors has bene-
ficial outcomes. Although these studies
represent an important contribution to
the understanding of the pathophysiology
of HD, this disease involves multiple
organs, multiple brain regions and
changes in numerous neurotransmitter
and receptor systems. It is probable that
combination drug therapies, accounting
for the multiple brain areas affected, the
different ways they are affected, and the
progression of the symptoms of HD, will
provide the most efficacious approach
to treatments.
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Hypothalamic dopamine neurons inhibit pituitary prolactin secretion. In this issue of Neuron, Lyons et al.
provide evidence for a novel model, whereby the excitatory neuropeptide TRH depolarizes gap-junction-
coupled dopamine neurons, leading to a shift in the population pattern of action potentials from phasic burst
firing to regular tonic firing, hypothetically reducing dopamine release while increasing total spike number.Prolactin is a fascinating pituitary hor-
mone that promotes milk synthesis during
lactation; its chemical structure is similar
to that of growth hormone. Prolactin
also enhances maternal behavior, and
paternal behavior in some species, modu-
lates immune responses, and is luteotro-
phic. Prolactin has also been associated
with reduced fertility during lactation,
thereby enhancing the direction of mater-
nal energy stores toward a new infant
rather than toward pregnancy (Freeman
et al., 2000). Most of the functions of
prolactin, including lactation, are carried
out in concert with other hormones
that collaborate to achieve a functional
response.Hypothalamic peptides released by
axons in the median eminence regulate
hormones synthesized and released by
the anterior pituitary, or adenohypoph-
ysis. In contrast to other pituitary hor-
mones that are controlled by releasing
factors, secretion of prolactin is controlled
by an inhibiting factor, dopamine. Dopa-
mine is synthesized by a subset of
neurons in the hypothalamic arcuate
nucleus, sometimes called tuberoinfun-
dibular dopamine (TIDA) neurons, that
release the monoamine from axon termi-
nals in the median eminence. Dopamine
is then carried by the portal blood system
to the pituitary where it activates dopa-
mine G protein coupled D2 receptorsthat reduce cAMP and attenuate pro-
lactin release, synthesis, and division of
prolactin cells. The current model of
CNS control of prolactin secretion is
based on the view that when dopamine
neurons in the arcuate nucleus stop
firing, this leads to a loss of dopamine-
mediated inhibition of the prolactin-
secreting cells, thereby increasing pro-
lactin release.
In a new paper in Neuron, Lyons, Hor-
jales-Araujo, and Broberger (Lyons et al.,
2010) from the Karolinska Institute in
Sweden record from hypothalamic slices,
and demonstrate for the first time that
arcuate dopamine neurons show phasic
bursts of spikes (20 spikes over 4–5 s), January 28, 2010 ª2010 Elsevier Inc. 147
